[1] Leach MO, Brindle KM, Evelhoch JL, et al.The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations[J].Br J Cancer, 2005, 92(9): 1599-1610.
[2] Patlak CS, Blasberg RG.Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.Generalizations[J].J Cereb Blood Flow Metab, 1985, 5(4): 584-590.
[3] Tofts PS, Kermode AG.Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging.1.Fundamental concepts[J].Magn Reson Med, 1991, 17(2): 357-367.
[4] St Lawrence KS, Lee TY.An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I.Theoretical derivation[J].J Cereb Blood Flow Metab, 1998, 18(12): 1365-1377.
[5] Tofts PS, Brix G, Buckley DL, et al.Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols[J].J Magn Reson Imaging, 1999, 10(3): 223-232.
[6] Leach MO, Morgan PS, Tofts PS, et al.Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging [J].Eur Radiol, 2012, 22(7): 1451-1464.
[7] Tozer GM.Measuring tumor vascular response to antivascular and antiangiogenic drugs[J].Br J Radiol, 2003, 76(1): S23-35.
[8] Gregorc V, Citterio G, Vitali G, et al.Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours[J].Eur J Cancer, 2010, 46(1): 198-206.
[9] Murukesh N, Dive C, Jayson GC, et al.Biomarkers of angiogenesis and their role in the development of VEGF inhibitors[J].Br J Cancer, 2010, 102(1): 8-18.
[10] Padhani AR.MRI for assessing antivascular cancer treatments[J].Br J Radiol, 2003, 76(1): S60-80.
[11]

Yung WK, Friedman H, Conrad C, et al.A phase Ⅰ trial of single-agent PTK 787/ZK 222584(PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme[C].Chicago: American Society of Clinical Oncology, 2003: 395.
[12] Cha S, Knopp EA, Johnson G, et al.Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin[J].AJNR Am J Neuroradiol, 2000, 21(5): 881-890.
[13] Parker GJ, Suckling J, Tanner SF, et al.Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics [J].J Magn Reson Imaging, 1997, 7(3): 564-574.
[14] Anwar RP, Janet EH.Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies[J].Clin Radiol, 2001, 56(8): 607-620.
[15] Buckley DL, Drew PJ, Mussurakis S, et al.Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI [J].J Magn Reson Imaging, 1997, 7(3): 461-464.
[16] Stomper PC, Winston JS, Herman S, et al.Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions[J].Breast Cancer Res Treat, 1997, 45(1): 39-46.
[17] Knopp MV, Weiss E, Sinn HP, et al.Pathophysiologic basis of contrast enhancement in breast tumors[J].J Magn Reson Imaging, 1999, 10(3): 260-266.
[18] O′Connor JP, Clamp AR, Carano RA, et al.Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging[J].Clin Cancer Res, 2009, 15(21): 6674-6682.
[19] Dowlati A, Robertson K, Cooney F, et al.A phase Ⅰ pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4-phosphate on a single-dose intravenous schedule in patients with advanced cancer[J].Cancer Res, 2002, 62(12): 3408-3416.
[20] Galbraith SM, Rustin GJ, Lodge MA, et al.Effects of 5, 6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging[J].J Clin Oncol, 2002, 20(18): 3826-3840.
[21] O′Cornor JP, Jackson A, Parker GJ, et al.Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies[J].Nat Rev Clin Oncol, 2012, 9(3): 167-177.
[22] Evelhoch JL.Key factors in the acquisition of contrast kinetic data for oncology[J].J Magn Reson Imaging, 1999, 10(3): 254-259.
[23] Thorpe PE.Vascular targeting agents as cancer therapeutics[J].Clin Cancer Res, 2004, 10(2): 415-427.
[24] McPhail LD, Griffiths JR, Robinson SP.Assessment of tumor response to the vascular disrupting agents 5, 6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging[J].Int J Radiat Oncol Biol Phys, 2007, 69(4): 1238-1245.
[25] Koh DM, Blackledge M, Collins DJ, et al.Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin-A4 phosphate and bevacizumab in a two-centre phase Ⅰ clinical trial[J].Eur Radiol, 2009, 19(11): 2728-2738.
[26] Galbraith SM, Maxwell RJ, Lodge MA, et al.Combretastatin-A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging[J].J Clin Oncol, 2003, 21(15): 2831-2842.
[27] Gregorc V, Citterio G, Vitati G, et al.Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours[J].Eur J Cancer, 2010, 46(1): 198-206.
[28] Jonker DJ, Rosen LS, Sawyer MB, et al.A phase Ⅰ study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors [J].Ann Oncol, 2011, 22(6): 1413-1419.
[29] Jackson A, O′Connor JP, Parker GJ, et al.Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging[J].Clin Cancer Res, 2007, 13(12): 3449-3459.
[30] O′Connor JP, Jackson A, Parker GJ, et al.DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents[J].Br J Cancer, 2007, 96(2): 189-195.
[31] Rehman S, Jayson GC.Molecular imaging of antiangiogenic agents [J].Oncologist, 2005, 10(2): 92-103.
[32]

Congress U.S.Food and drug administration modernization act of 1997[R].Virginia: U.S.FDA, 1997: 105-115.
[33] Hahn OM, Yang C, Medved M, et al.Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma[J].J Clin Oncol, 2008, 26(28): 4572-4578.
[34] Dahut WL, Madan RA, Karakunnel JJ, et al.Phase Ⅱ clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer[J].BJU Int, 2013, 111(8): 1269-1290.
[35] Kreisl TN, Zhang W, Odia Y, et al.A phase Ⅱ trial of single-agent bevacizumab in patients with recurrent anaplastic glioma[J].Neuro Oncol, 2011, 13(10): 1143-1150.
[36] Lockhart AC, Rosenberg ML, Dupont J, et al.Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors[J].J Clin Oncol, 2010, 28(2): 207-214.
[37] Zhu AX, Sahani DV, Duda DG, et al.Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase Ⅱ study[J].J Clin Oncol, 2009, 27(18): 3027-3035.
[38] Liu G, Hope S, Wilding G, et al.Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase Ⅰ study[J].J Clin Oncol, 2005, 23(24): 5464-5473.